Head to Head Comparison: Labcorp (NYSE:LH) & IceCure Medical (NASDAQ:ICCM)

IceCure Medical (NASDAQ:ICCM) and Labcorp (NYSE:LH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for IceCure Medical and Labcorp, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1	1	1	0	2.00
Labcorp	0	3	9	0	2.75

IceCure Medical presently has a consensus target price of $2.64, suggesting a potential upside of 839.39%. Labcorp has a consensus target price of $304.82, suggesting a potential upside of 15.59%. Given IceCure Medical’s higher probable upside, research analysts plainly believe IceCure Medical is more favorable than Labcorp.

Profitability

This table compares IceCure Medical and Labcorp’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-445.61%	-221.04%	-118.89%
Labcorp	6.28%	16.16%	7.62%

Institutional and Insider Ownership

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 0.8% of Labcorp shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

IceCure Medical has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Labcorp has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Valuation & Earnings

This table compares IceCure Medical and Labcorp”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38 million	6.07	-$15.06 million	($0.24)	-1.17
Labcorp	$13.95 billion	1.56	$876.50 million	$10.46	25.21

Labcorp has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Summary

Labcorp beats IceCure Medical on 11 of the 14 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Labcorp

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.